Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of BO-112 when given together with nivolumab
before surgery in treating patients with soft tissue sarcoma that can be removed by surgery
(resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and
may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112
before surgery may work better in treating patients with soft tissue sarcoma compared to
nivolumab alone.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Highlight Therapeutics National Cancer Institute (NCI)